Eribulin mesylate in Indian patients: A single center experience.
Loading...
Date
2015-07
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
BACKGROUND: Eribulin mesylate is the latest addition in the armamentarium of management of metastatic breast cancer (MBC) with a unique
mechanism of action. Although the multicentric EMBRACE trial suggests significant overall survival benefit from this novel drug, its effectiveness
in Indian population is yet to be evaluated. MATERIALS AND METHODS: Presented here is a single center experience of eight patients who were
administered eribulin for MBC. Patients had received a median of 3 prior chemotherapies before eribulin administration. The median dose of
eribulin therapy was 5 cycles (range: 2–6 cycles). RESULTS: The objective response rate was 75% (CR in one and PR in five out of eight patients).
Response was seen across all subtypes of patients. Eribulin was well tolerated. No serious adverse events were reported. CONCLUSION: Eribulin
conferred good response rates with satisfactory tolerability profile in Indian patients. Its use in earlier lines and in combination with other drugs
may achieve deeper and longer responses.
Description
Keywords
Eribulin, metastatic breast cancer, overall survival
Citation
Thippeswamy R, Patil S, Shashidara H P, Satheesh C T, Vittal H, Mishra S. Eribulin mesylate in Indian patients: A single center experience. Indian Journal of Cancer. 2015 July-Sept; 52(3): 297-298.